# A Clinical Trial of CK0801 (a New Drug) In Patients With Treatment-Resistant Guillain-Barré Syndrome (GBS)

> **NCT03773328** · PHASE1 · WITHDRAWN · sponsor: **Cellenkos, Inc.**

## Conditions studied

- Guillain-Barré Syndrome

## Interventions

- **BIOLOGICAL:** CK0801

## Key facts

- **NCT ID:** NCT03773328
- **Lead sponsor:** Cellenkos, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-11
- **Primary completion:** 2025-02
- **Final completion:** 2027-02
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Pending contract negotiations
- **Last updated:** 2023-01-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03773328

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03773328, "A Clinical Trial of CK0801 (a New Drug) In Patients With Treatment-Resistant Guillain-Barré Syndrome (GBS)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03773328. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*